Han W. Tun

3.8k total citations
144 papers, 2.7k citations indexed

About

Han W. Tun is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Han W. Tun has authored 144 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pathology and Forensic Medicine, 58 papers in Genetics and 44 papers in Oncology. Recurrent topics in Han W. Tun's work include Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (41 papers) and CNS Lymphoma Diagnosis and Treatment (39 papers). Han W. Tun is often cited by papers focused on Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (41 papers) and CNS Lymphoma Diagnosis and Treatment (39 papers). Han W. Tun collaborates with scholars based in United States, Italy and China. Han W. Tun's co-authors include Christina A. Von Roemeling, John A. Copland, Laura A. Marlow, Simon Cooper, Deepak Choudhury, Tianyi Wang, May Win Naing, Kevin J. Wu, Thomas R. Caulfield and David M. Menke and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Han W. Tun

129 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Han W. Tun United States 25 1.1k 695 518 499 478 144 2.7k
Naoki Shinojima Japan 26 1.3k 1.2× 262 0.4× 682 1.3× 602 1.2× 1.3k 2.7× 80 3.0k
José Cameselle‐Teijeiro Spain 39 1.6k 1.5× 791 1.1× 1.6k 3.1× 670 1.3× 170 0.4× 143 4.3k
Arman Jahangiri United States 28 913 0.8× 151 0.2× 390 0.8× 549 1.1× 593 1.2× 66 2.8k
Gregory M. Coté United States 35 1.3k 1.2× 411 0.6× 1.3k 2.5× 485 1.0× 159 0.3× 151 3.4k
Ali G. Turhan France 37 1.5k 1.4× 332 0.5× 1.0k 2.0× 310 0.6× 1.4k 2.9× 184 4.0k
John Sarantopoulos United States 28 1.6k 1.5× 257 0.4× 1.3k 2.5× 382 0.8× 238 0.5× 143 3.2k
Boris K. Lin United States 26 2.8k 2.5× 505 0.7× 1.6k 3.0× 241 0.5× 543 1.1× 50 4.4k
Brett L. Carlson United States 29 1.9k 1.7× 248 0.4× 1.3k 2.4× 725 1.5× 1.4k 3.0× 69 3.6k
David J. Shields United States 23 1.7k 1.6× 122 0.2× 648 1.3× 634 1.3× 275 0.6× 44 3.2k

Countries citing papers authored by Han W. Tun

Since Specialization
Citations

This map shows the geographic impact of Han W. Tun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han W. Tun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han W. Tun more than expected).

Fields of papers citing papers by Han W. Tun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Han W. Tun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han W. Tun. The network helps show where Han W. Tun may publish in the future.

Co-authorship network of co-authors of Han W. Tun

This figure shows the co-authorship network connecting the top 25 collaborators of Han W. Tun. A scholar is included among the top collaborators of Han W. Tun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Han W. Tun. Han W. Tun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Jacqueline, Jihao Zhou, Han W. Tun, et al.. (2024). Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study. Blood. 144(Supplement 1). 1637–1637.
2.
Huntington, Scott F., Stephen J. Schuster, Wei Ding, et al.. (2023). DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal of Hematology. 98(5). 739–749. 7 indexed citations
3.
4.
Moustafa, Muhamad Alhaj, Bijan J. Borah, James P. Moriarty, et al.. (2023). Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 23(4). 259–265. 1 indexed citations
5.
6.
Baidoun, Firas, Muhamad Alhaj Moustafa, Han W. Tun, & Brian T. Hill. (2022). Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study. Clinical Lymphoma Myeloma & Leukemia. 22(7). e485–e494. 9 indexed citations
7.
Parrondo, Ricardo, et al.. (2022). Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation. SHILAP Revista de lepidopterología.
8.
9.
Jiang, Liuyan, et al.. (2022). Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes. Journal of Blood Medicine. Volume 13. 663–671.
10.
Moustafa, Muhamad Alhaj, Liuyan Jiang, Madiha Iqbal, et al.. (2022). Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clinical Lymphoma Myeloma & Leukemia. 22(8). e815–e825. 2 indexed citations
11.
Moustafa, Muhamad Alhaj, et al.. (2021). Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review. Journal of Blood Medicine. Volume 12. 645–652. 5 indexed citations
12.
Seegobin, Karan, et al.. (2021). Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. Journal of Blood Medicine. Volume 12. 1037–1043. 3 indexed citations
13.
Iqbal, Madiha, Jonas Paludo, Allison Rosenthal, et al.. (2021). Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 22(2). e89–e95. 2 indexed citations
14.
Moustafa, Muhamad Alhaj, et al.. (2021). Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis. SHILAP Revista de lepidopterología. 9(5). e03971–e03971. 1 indexed citations
15.
Drake, Richard R., Connor A. West, Thomas W. Powers, et al.. (2019). Defining the human kidney N‐glycome in normal and cancer tissues using MALDI imaging mass spectrometry. Journal of Mass Spectrometry. 55(4). e4490–e4490. 50 indexed citations
16.
Dholaria, Bhagirathbhai, Prakash Vishnu, Vivek Roy, et al.. (2017). DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience. Blood. 130. 1572–1572.
17.
Witzig, Thomas E., Craig B. Reeder, Jing Han, et al.. (2015). The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 126(3). 328–335. 83 indexed citations
18.
Roemeling, Christina A. Von, Derek C. Radisky, Laura A. Marlow, et al.. (2014). Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4. Cancer Research. 74(17). 4796–4810. 156 indexed citations
19.
Roemeling, Christina A. Von, Laura A. Marlow, Simon Cooper, et al.. (2013). Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 19(9). 2368–2380. 224 indexed citations
20.
Cooper, Simon, Christina A. Von Roemeling, Laura A. Marlow, et al.. (2012). Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers. Molecular Cancer Therapeutics. 11(10). 2105–2115. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoki Shinojima Breakdown of academic impact, for papers by José Cameselle‐Teijeiro Breakdown of academic impact, for papers by Arman Jahangiri Breakdown of academic impact, for papers by Gregory M. Coté Breakdown of academic impact, for papers by Ali G. Turhan Breakdown of academic impact, for papers by John Sarantopoulos Breakdown of academic impact, for papers by Boris K. Lin Breakdown of academic impact, for papers by Brett L. Carlson Breakdown of academic impact, for papers by David J. Shields
Rankless by CCL
2026